Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | +4.42% | +11.18% | -83.83% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.89M 712M |
---|---|---|---|---|---|
Net income 2024 * | -31M -2.48B | Net income 2025 * | -34M -2.72B | EV / Sales 2024 * | - |
Net cash position 2024 * | 22M 1.76B | Net cash position 2025 * | 58M 4.64B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.37
x | P/E ratio 2025 * |
-0.93
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.06% |
Latest transcript on eFFECTOR Therapeutics, Inc.
1 day | +4.42% | ||
1 week | +11.18% | ||
Current month | -86.87% | ||
1 month | -85.95% | ||
3 months | -82.09% | ||
6 months | -85.73% | ||
Current year | -83.83% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 30/04/12 |
Michael Byrnes
DFI | Director of Finance/CFO | 47 | 30/11/20 |
Douglas Warner
CTO | Chief Tech/Sci/R&D Officer | 52 | 07/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 30/04/12 |
Director/Board Member | 54 | 24/08/21 | |
Caroline Loewy
BRD | Director/Board Member | 58 | 10/09/23 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.89 | +4.42% | 162,186 |
25/04/24 | 1.81 | -2.16% | 180,978 |
24/04/24 | 1.85 | -4.64% | 108,175 |
23/04/24 | 1.94 | +8.99% | 149,714 |
22/04/24 | 1.78 | +4.71% | 177,232 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.83% | 8.89M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- EFTR Stock